PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30242487-2 2018 The monoamine oxidases A and B (MAOA/MAOB) are prime candidates for the investigation into the role of DNA methylation in mental disorders, given their pivotal role in the metabolism of monoamines and as pharmacological targets of potent antidepressant drugs such as tranylcypromine, phenelzine or moclobemide. Tranylcypromine 267-282 monoamine oxidase B Homo sapiens 37-41 32094232-7 2020 Using either HuH-7 cell lysates or recombinant human MAOB, we found (i) that the MAO inhibitor tranylcypromine dose-dependently down-regulates endogenous GGA levels in HuH-7 cells, and (ii) that siRNA-mediated MAOB silencing reduces intracellular GGA levels in HuH-7 and Hep3B cells. Tranylcypromine 95-110 monoamine oxidase B Homo sapiens 53-57 32094232-7 2020 Using either HuH-7 cell lysates or recombinant human MAOB, we found (i) that the MAO inhibitor tranylcypromine dose-dependently down-regulates endogenous GGA levels in HuH-7 cells, and (ii) that siRNA-mediated MAOB silencing reduces intracellular GGA levels in HuH-7 and Hep3B cells. Tranylcypromine 95-110 monoamine oxidase B Homo sapiens 210-214 29031059-2 2017 Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1. Tranylcypromine 0-15 monoamine oxidase B Homo sapiens 112-117 29031059-2 2017 Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1. Tranylcypromine 17-20 monoamine oxidase B Homo sapiens 112-117 25755053-10 2015 This cis-cyclopropylamine is over 20-fold more effective than tranylcypromine, so may be studied as a lead for selective inhibitors of MAO B that do not inhibit LSD1. Tranylcypromine 62-77 monoamine oxidase B Homo sapiens 135-140 24601544-4 2014 Docking and molecular dynamics were used to explore how 2-(2-benzofuranyl)-2-imidazoline hydrochloride (2-BFI) binds to MAO A and to explain why tranylcypromine increases tight binding to MAO B. Tranylcypromine 145-160 monoamine oxidase B Homo sapiens 188-193 24601544-5 2014 The energy for 2-BFI binding to MAO A was comparable to that for tranylcypromine-modified MAO B, but the location of 2-BFI in the MAO A could be anywhere in the monopartite substrate cavity. Tranylcypromine 65-80 monoamine oxidase B Homo sapiens 90-95 24601544-6 2014 Binding to the tranylcypromine-modified MAO B was with high affinity and in the entrance cavity as in the crystal structure, but the energies of interaction with the native MAO B were less favorable. Tranylcypromine 15-30 monoamine oxidase B Homo sapiens 40-45 24601544-6 2014 Binding to the tranylcypromine-modified MAO B was with high affinity and in the entrance cavity as in the crystal structure, but the energies of interaction with the native MAO B were less favorable. Tranylcypromine 15-30 monoamine oxidase B Homo sapiens 173-178 24601544-7 2014 Molecular dynamics revealed that the entrance cavity of MAO B after tranylcypromine modification is both smaller and less flexible. Tranylcypromine 68-83 monoamine oxidase B Homo sapiens 56-61 24601544-8 2014 This change in the presence of tranylcypromine may be responsible for the greater affinity of tranylcypromine-modified MAO B for imidazoline ligands. Tranylcypromine 31-46 monoamine oxidase B Homo sapiens 119-124 24601544-8 2014 This change in the presence of tranylcypromine may be responsible for the greater affinity of tranylcypromine-modified MAO B for imidazoline ligands. Tranylcypromine 94-109 monoamine oxidase B Homo sapiens 119-124 17367163-7 2007 2-PCPA shows limited selectivity for human MAOs versus LSD1, with kinact/KI values only 16-fold and 2.4-fold higher for MAO B and MAO A, respectively. Tranylcypromine 0-6 monoamine oxidase B Homo sapiens 120-125 20832472-3 2010 We here confirm previous reports that inactivation of recombinant human MAO-B with tranylcypromine results in the formation of a high affinity I(2) site on the enzyme, measured as an increase in binding of [(3)H]2-BFI. Tranylcypromine 83-98 monoamine oxidase B Homo sapiens 72-77 20832472-4 2010 Incubation of MAO-B with 2-phenylethylamine, an endogenous trace amine and MAO-B substrate, resulted in a progressive loss of enzyme activity, increased enzyme mass, distinct spectral changes and, as was observed with tranylcypromine, a parallel increase in high affinity binding of [(3)H]2-BFI. Tranylcypromine 218-233 monoamine oxidase B Homo sapiens 14-19 20568732-3 2010 In this study, we designed and synthesized several candidate compounds to inhibit LSD1, based on the structures of LSD1 and monoamine oxidase B (MAO-B), in complex with an antidepressant tranylcypromine (2-PCPA) derivative. Tranylcypromine 187-202 monoamine oxidase B Homo sapiens 124-143 20568732-3 2010 In this study, we designed and synthesized several candidate compounds to inhibit LSD1, based on the structures of LSD1 and monoamine oxidase B (MAO-B), in complex with an antidepressant tranylcypromine (2-PCPA) derivative. Tranylcypromine 187-202 monoamine oxidase B Homo sapiens 145-150 9829163-3 1998 While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction. Tranylcypromine 82-97 monoamine oxidase B Homo sapiens 212-231 12913124-7 2003 Inhibition of MAO-B with the clinically used trans-2-phenylcyclopropylamine results in the formation of a covalent C(4a) flavin adduct with an opened cyclopropyl ring and the phenyl ring in a parallel orientation to the flavin. Tranylcypromine 45-75 monoamine oxidase B Homo sapiens 14-19 12504917-8 2002 ), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors. Tranylcypromine 119-134 monoamine oxidase B Homo sapiens 110-115 15279562-4 2004 The recent development of high level expression systems for producing recombinant human liver MAO A and MAO B in Pichia pastoris has facilitated the determination of the three dimensional crystal structures of MAO B (up to 1.7 angstroms resolution) in complex with different reversible (isatin, 1,4-diphenyl-2-butene) and irreversible inhibitors (pargyline, N-(2-aminoethyl)-p-chlorobenzamide, and trans-2-phenylcyclopropylamine). Tranylcypromine 398-428 monoamine oxidase B Homo sapiens 210-215 9829163-3 1998 While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction. Tranylcypromine 82-97 monoamine oxidase B Homo sapiens 233-238 6871302-0 1983 Tranylcypromine lowers human platelet MAO B activity but not concentration. Tranylcypromine 0-15 monoamine oxidase B Homo sapiens 38-43 2875125-3 1986 In humans treated with the MAO-A selective inhibitor, clorgyline, or the nonselective inhibitor, tranylcypromine, increased plasma melatonin also occurs; in contrast, the MAO-B selective inhibitor, 1-deprenyl, does not affect plasma melatonin. Tranylcypromine 97-112 monoamine oxidase B Homo sapiens 171-176 33775841-1 2021 Tranylcypromine (TCP)-based structural modifications lead to the discovery of new LSD1 inhibitors, of which compounds 26b and 29b effectively inhibit LSD1 with the IC50 values of 17 and 11 nM, respectively and also show good selectivity over MAO-B. Tranylcypromine 0-15 monoamine oxidase B Homo sapiens 242-247 33775841-1 2021 Tranylcypromine (TCP)-based structural modifications lead to the discovery of new LSD1 inhibitors, of which compounds 26b and 29b effectively inhibit LSD1 with the IC50 values of 17 and 11 nM, respectively and also show good selectivity over MAO-B. Tranylcypromine 17-20 monoamine oxidase B Homo sapiens 242-247 35208214-2 2022 Recently, we found that monoamine oxidase B (MAOB) catalyzed the oxidation of geranylgeraniol (GGOH) to produce geranylgeranial (GGal), a direct precursor of endogenous GGA in hepatoma cells, using tranylcypromine, an inhibitor of MAOs, and knockdown by MAOB siRNA. Tranylcypromine 198-213 monoamine oxidase B Homo sapiens 24-43 35208214-2 2022 Recently, we found that monoamine oxidase B (MAOB) catalyzed the oxidation of geranylgeraniol (GGOH) to produce geranylgeranial (GGal), a direct precursor of endogenous GGA in hepatoma cells, using tranylcypromine, an inhibitor of MAOs, and knockdown by MAOB siRNA. Tranylcypromine 198-213 monoamine oxidase B Homo sapiens 45-49 35208214-2 2022 Recently, we found that monoamine oxidase B (MAOB) catalyzed the oxidation of geranylgeraniol (GGOH) to produce geranylgeranial (GGal), a direct precursor of endogenous GGA in hepatoma cells, using tranylcypromine, an inhibitor of MAOs, and knockdown by MAOB siRNA. Tranylcypromine 198-213 monoamine oxidase B Homo sapiens 254-258 20501066-6 1987 They could be protected by the presence of the substrate (phenylethylamine) or inhibitors (pargyline and trans-phenylcyclopropylamine) of MAO-B during photolysis. Tranylcypromine 105-133 monoamine oxidase B Homo sapiens 138-143 6871302-4 1983 Since recovery of MAO B activity approximated the reported half-life of blood platelets, these results suggest that recovery of platelet MAO activity after tranylcypromine treatment is due to the replacement of old platelets by new ones which contain catalytically active MAO B. Tranylcypromine 156-171 monoamine oxidase B Homo sapiens 272-277